Open | $5.520 |
Close | - |
Volume / Avg. | 13.520K / 322.944K |
Day Range | 5.520 - 5.710 |
52 Wk Range | 2.000 - 7.223 |
Market Cap | $171.565M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 53 |
Short Interest | 5.86% |
Days to Cover | 4.74 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Relmada Therapeutics (NASDAQ: RLMD) through any online brokerage.
Other companies in Relmada Therapeutics’s space includes: Zevra Therapeutics (NASDAQ:ZVRA), Xeris Biopharma Holdings (NASDAQ:XERS), Alimera Sciences (NASDAQ:ALIM), Telomir Pharmaceuticals (NASDAQ:TELO) and Trevi Therapeutics (NASDAQ:TRVI).
The latest price target for Relmada Therapeutics (NASDAQ: RLMD) was reported by Mizuho on Thursday, June 15, 2023. The analyst firm set a price target for 26.00 expecting RLMD to rise to within 12 months (a possible 356.14% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Relmada Therapeutics (NASDAQ: RLMD) is $5.7 last updated Today at March 19, 2024 at 9:48 AM EDT.
There are no upcoming dividends for Relmada Therapeutics.
Relmada Therapeutics’s Q1 earnings are confirmed for Thursday, May 9, 2024.
There is no upcoming split for Relmada Therapeutics.
Relmada Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.